Bionor Pharma ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bionor Pharma ASA Completes Private Placement and Proposes Repair Offer
Bionor Pharma ASA announced that the Private Placement announced on September 12, 2013 of 19,800,000 new shares at a subscription price of NOK 2.75 per share has been oversubscribed raising NOK 54.45 million in gross proceeds. The Board of Directors has resolved to propose that the Extraordinary General Meeting of the Company scheduled for October 7, 2013 resolves a subsequent repair issue directed towards the shareholders in Bionor as of close of the Oslo Stock Exchange on September 12, 2013 (as registered in the VPS on September 17, 2013) who were not allocated shares in the Private Placement (the Repair Offer). These shareholders will, pursuant to the proposed resolution, be entitled to subscribe up to a total of 7,500,000 new shares at a subscription price of NOK 2.75 per share (total proceeds up to NOK 20.6 million).
Latest Developments for Bionor Pharma ASA
- Bionor Pharma ASA Announces Private Placement
- Bionor Pharma ASA Announces Successful Completion of First Part of Phase II Clinical Study Combining the HIV Vaccine Vacc-4x with Celgene's Immunomodulator Lenalidomide (Revlimid)
- Bionor Pharma ASA Appoints Dr. Anker Lundemose New President and Chief Executive Officer
- Bionor Pharma ASA's Chief Executive Officer to Resign
- Share this
- Digg this